

# MEDICAL VALUE BY **MEDICAL VALLEY**

Two Decades of Evidenced-based Outcomes Research:

The Erlangen Stroke Registry



Prof. Dr. Peter Kolominsky-Rabas, MD, PhD, MBA
Interdisciplinary Center for Health Technology Assessment (HTA) and Public Health
Friedrich-Alexander-University Erlangen-Nürnberg, Bavaria, Germany
National Cluster of Excellence ,Medical Technologies - Medical Valley EMN'

# Erlangen Stroke Registry – Study Design




- Location in south of Germany, northern Bavaria
- longitudinal study (started in 1994)
- prospective
- population of 108.000 inhabitans
- well-defined geographic area





# Erlangen Stroke Registry - Geographical Area





# Erlangen Stroke Registry - Study Criteria



Source population all residents of Erlangen (Community Registration Office)

Age no restriction of age

Case ascertainment hospitalized non-hospitalized stroke-patients

Follow-up

3 months

12 months

yearly follow-up (according to Helsingborg Declaration)
home visits with f2f interviews





# Gold Standards for an "Ideal" Stroke Study



### 1. Complete case ascertainment

Concept of ,overlapping sources of information' to ensure complete case ascertainment

### Regular checks of:

- hospital wards
- residential and nursing homes
- records of ambulance and emergency services
- general practitioners
- death certificates

Reference: Malmgren at al., Lancet 1987; Sudlow & Warlow, Stroke 1996; Feigin et al., Lancet 2004





# Gold Standards for an "Ideal" Stroke Study (Cont.)



2. Specification of diagnosis/ exclusion of stroke-like events

Diagnosis of stroke
Diagnostic criteria

WHO stroke definition

Classification of stroke subtypes
Brain CT-scan at admission

CT scan rate of 98%

Etiology of ischemic stroke
TOAST-classification

Reference: Malmgren at al., Lancet 1987; Sudlow & Warlow, Stroke 1996; Feigin et al., Lancet 2004





### Erlangen Stroke Registry - Outcome variables



Cinical assessment (acute)
NIHSS

modified Rankin Scale

ABDC2 score (TIA)

Risk factors assessment
CHA2DS2-VASc Score

TOAST- classification (Adams et al. 1998)

Clinical assessment (long-term)
Barthel Index

Functional Independence Measure

Frenchay Activity Index

Social Support Scale

Cognitive assessment
MMST

**Depression Status Inventory** 

SF-36


Quality of Life SF-36

Care Giver Burden Scale



### Resource Use of Stroke Servivors







# Direct cost of ischemic stroke by time horizon Statutory Health Insurance in Germany (Euros, discounted)



Horizon	Men	Women	All	
1 y	15,566	14,799	15,140	
5 y	30,159	29,582		/ % o time
10 y	37,711	36,176	36,873	
Lifetime	45,549	41,304	43,129	

Reference: Kolominsky-Rabas at al., Stroke 2006





# National Direct Ischemic Stroke Cost Projections Statutory Health Insurance in Germany



	Men		Women		All	
Horizon	Strokes	Cost (Billion)	Strokes	Cost (Billion)	Strokes	Cost (Billion)
2006-2010	331,000	13.8	425,000	16.1	756,000	29.9
2006-2015	701,000	27.1	880,000	30.9	1,581,000	58.0
2006-2020	1,108,000	39.7	1,367,000	44.6	2,475,000	84.3
2006-2025	1,547,000	51.5	1,883,000	57.1	3,430,000	108.6



### Erlangen Stroke Registry - Cost-of-Illness of Stroke



European Journal of Neurology 2005, 12: 264-267

### Care needs and economic consequences after acute ischemic stroke: the Erlangen Stroke Project

A. Ward<sup>a</sup>, K. A. Payne<sup>b</sup>, J. J. Caro<sup>a,c</sup>, P. U. Heuschmann<sup>d</sup> and P. L. Kolominsky-Rabas<sup>e</sup>
<sup>a</sup>Caro Research Institute, Concord, MA, USA; <sup>b</sup>Caro Research Institute, Montreal, Quebec, Canada; <sup>a</sup>Division of General Internal Medicine,
Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada; <sup>d</sup>Institute of Epidemiology and Social Medicine, University of
Muenster, Germany; <sup>e</sup>Unit for Stroke Research and Public Health Medicine, University of Erlangen, Bavaria, Germany

#### Keywords:

acute ischemic stroke, care needs, costs, Erlangen Stroke Project, Germany

Received 17 May 2004 Accepted 7 July 2004

The objective was to determine the fi consequences in the first 3 months Stroke Project, (ESPro) information ischemic stroke. Three months after caregivers and function based on E good function (95-100) were recorded with cost estimates for Germany (2) pitalized, 383 were alive 3 months a majority of patients with poor functi with good function typically accru (17 965) or not (11 032) compared tution (poor: 26 370; moderate: 28 19,350). Hospitalization and rehabi each level of function. Many patient and the costs associated with provid economic consequences of a stroke.

### Lifetime Cost of Ischemic Stroke in Germany: Results and National Projections From a Population-Based Stroke Registry The Erlangen Stroke Project

Peter L. Kolominsky-Rabas, MD, PhD; Peter U. Heuschmann, MD, PhD; Daniela Marschall, MSc; Martin Emmert; Nikoline Baltzer, Bnurs; Bernhard Neundörfer, MD, PhD; Oliver Schöffski, PhD; Karl J. Krobot, MD, PhD; for the CompetenceNet Stroke

Background and Purpose—The number of stroke patients and the healthcare costs of strokes are expected to rise. The objective of this study was to determine the direct costs of first ischemic stroke and to estimate the expected increase in costs in Germany.

Methods—An incidence-based, bottom-up, direct-cost-of-ischemic-stroke study from the third-party payer's perspective was performed, incorporating 10-year survival data and 5-year resource use data from the Erlangen Stroke Registry. Discounted lifetime year 2004 costs per case were obtained and applied to the expected age and sex evolution of the German resident population in the period 2006 to 2025.

Results—The overall cost per first-year survivor of first-ever ischemic stroke was estimated to be 18 517 euros (EUR). Rehabilitation accounted for 37% of this cost, whereas in subsequent years outpatient care was the major cost driver. Discounted lifetime cost per case was 43 129 EUR overall and was higher in men (45 549 EUR) than in women (41 304 EUR). National projections for the period 2006 to 2025 showed 1.5 million and 1.9 million new cases of ischemic stroke in men and women, respectively, at a present value of 51.5 and 57.1 billion EUR, respectively.

Conclusions—The number of stroke patients and the healthcare costs of strokes in Germany will rise continuously until the year 2025. Therefore, stroke prevention and reduction of stroke-related disability should be made priorities in health planning policies. (Stroke. 2006;37:1179-1183.)

Key Words: costs and cost analysis ■ cost of illness ■ ischemic stroke ■ resource use ■ stroke



# Erlangen Stroke Registry - Long Term Outcome of Stroke







M. Dietl<sup>1</sup>, R. Pohle<sup>1,2</sup>, M. Weingärtner<sup>1,3</sup>, R. Polgar<sup>1</sup>, E. Gräßel<sup>1,4</sup>, S. Schwab<sup>3</sup>, P. Kolominsky-Rabas<sup>1,3</sup>

Interdisziplinäres Zentrum für Public Health (IZPH) der Universität Erlanger-Nürnberg
 (Geschäftsführer: PD Dr. P. Kolominsky-Rabas, MBA), Universitätsklinikum Erlangen
 Anästhesiologische Klinik (Direktor: Prof. Dr. Dr. J. Schöttler), Universitätsklinikum Erlangen
 Neurologische Klinik (Direktor: Prof. Dr. S. Schwab), Universitätsklinikum Erlangen
 Psychlatrische und Psychotherapeutische Klinik (Direktor: Prof. Dr. J. Kornhuber), Universitätsklinikum Erlangen

Autoren

# Erlangen Stroke Registry - Epidemiology



#### A Prospective Community-Based Study of Stroke in Germany—The Erlangen Stroke Project (ESPro) Incidence and Case Fatality at 1, 3, and 12 Months

Peter L. Kolominsky-Rabas, MD; Cinzia Sarti, MD, PhD; Peter Ulrich Heuschmann, MD; Christian Graf, MD; Sven Siemonsen, MD; Bernhard Neundoerfer, MD, PhD; Alexandar Katalinic, MD; Erich Lang, MD, PhD; Karl-Günther Gassmann, MD; Theodor Ritter von Stockert, MD

Background and Purpose—In Germany, basic data on str former East Germany is excluded, only routine mortality of stroke. Therefore, a population-based register of stroke case fatality in a defined German population.

Methods—The Erlangen Stroke Project (ESPro) is a prospethe city of Erlangen, Bavaria, Germany, Standard defiidentify all cases of first-ever stroke in all age-groups, oc 31, 1996). All identified cases of first-ever strokes were

Results—During 2 years of registration, 354 first-ever-in-a stroke type were confirmed by CT scan in 95% of cases, years of age. The crude annual incidence rate was 1 age-adjustment to the European oppulation, the incidence The annual crude incidence rate of cerebral infarction was hemorrhage 0.06/1000, and unspecified stroke 0.08/1000. 28.5%, and at 1 year 37.3%.

Conclusions—The first prospective community-based stro incidence rates of stroke similar to those reported fro countries, but lower than that observed in former East G

Key Words: epidemiology ■ Germ

#### Variations in Stroke Incidence and Survival in 3 Areas of Europe

Charles D.A. Wolfe, MD; Maurice Giroud, MD; Peter Kolominsky-Rabas, MD; Ruth Dundas, MSe; Martine Lemesle, MD; Peter Heusehmann, MD; Anthony Rudd, FRCP; for the European Registries of Stroke (EROS) Collaboration

Background and Purpose—Comparison of incidence and our understanding of the etiology of the disease, its na population and the treaf for governments to set targ comparison of such data across countries may identify

Methods—Population-based stroke registers, using multip stroke between 1995 and 1997 for all age groups. The st London, UK. Crude incidence rates were age-standar Case-fatality rates up to 1 year after the stroke were ob pathological subtype of stroke was used to compare su

Results—A total of 2074 strokes were registered over the was 100.4 (95% cT 91.7 to 109.1) per 100 000 in Dijon 124.9 to 147.9) in Erlangen. Both crude and adjusted ra Dijon as the baseline comparison (1), was 1.21 (95% Erlangen (P<0.0001). There were significant differ populations, with London having lower rates of cerebr unclassified stroke (P<0.001). Case-fatality rates varied sex, and subtype of stroke (35% overall, 34% Erlangen.

Conclusions—The impact of stroke is considerable, and Europe as does the risk of death. The striking difference that stroke management may differ between nortl 2000;31:2074-2079.)

Key Words: epidemi

#### **Original Contributions**

#### Epidemiology of Ischemic Stroke Subtypes According to TOAST Criteria

Incidence, Recurrence, and Long-Term Survival in Ischemic Stroke Subtypes: A Population-Based Study

Peter L. Kolominsky-Rabas, MD; Margarete Weber, MD; Olaf Gefeller, MSe, PhD; Bernhard Neundoerfer, MD, PhD; Peter U. Heuschmann, MD, MPH

Background and Purpose—The purpose of this study warrates of ischemic stroke subtypes by a mechanism-bas Treatment, or TOAST).

Methods—We identified all 583 residents of the city of Er 1994 and 1998. Multiple overlapping sources of inform The cause of ischemic stroke was classified according and 1 and 2 years after stroke onset.

Results—The age-standardized incidence rates for the Is subtypes were as follows: cardioembolism, 30.2 (95% 30.9); and large-artery atherosclerosis, 15.3 (95% Ct 1 incidence rate for large-artery atherosclerosis was more 9.2/100 000). Two years after onset, patients in the smal than those with cardioembolism. Ischemic stroke subty for long-term survival, whereas subtype was not a signif and after adjustment for age and sex.

Conclusions—Epidemiological observational studies that apply standardized etiologic classifications provide a stroke, recurrence, and mortality. (Stroke. 2001;32:27)

Key Words: epidemiology ■ incidence

#### **Original Paper**

Neuro -epidemiology

Neuroepidemiology 2015;44:24–29 DOI: 10.1159/000371353 Received: August 5, 2014 Accepted: November 29, 2014 Published online: January 31, 2015

# Time Trends in Incidence of Pathological and Etiological Stroke Subtypes during 16 Years: The Erlangen Stroke Project

Peter L. Kolominsky-Rabas<sup>a</sup> Silke Wiedmann<sup>b</sup> Michael Weingärtner<sup>a</sup> Thomas G. Liman<sup>c</sup> Matthias Endres<sup>c</sup> Stefan Schwab<sup>d</sup> Michael Buchfelder<sup>e</sup> Peter U. Heuschmann<sup>b, f</sup>

\*Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen-Nürnberg, Brustitute of Clinical Epidemiology and Biometry, Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Cepartment of Neurology, Center for Stroke Research, Gernan Center for Neurodegenerative Diseases (DZNE), German Center for Cardiovascular Research (DZHK), Partner Site, Charlté - Universitätsmedizin Berlin, Serlin, "Department of Neurology," Department of Neurosurgery, University Hospital Krizburg, Würzburg, Germany





### Contact:

Prof. Dr. Peter Kolominsky-Rabas, MD, PhD, MBA
Interdisciplinary Center for Health Technology Assessment (HTA) and Public Health
Friedrich-Alexander-University Erlangen-Nürnberg, Bavaria, Germany
National Cluster of Excellence ,Medical Technologies - Medical Valley EMN'

peter.kolominsky@uk-erlangen.de